Gossamer Bio, Inc. (GOSS)
Largest Insider Buys in Sector
GOSS Stock Price History Chart
GOSS Stock Performance
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel …
Insider Activity of Gossamer Bio, Inc.
Over the last 12 months, insiders at Gossamer Bio, Inc. have bought $324,442 and sold $53,578 worth of Gossamer Bio, Inc. stock.
On average, over the past 5 years, insiders at Gossamer Bio, Inc. have bought $969,539 and sold $356,034 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hasnain Faheem (President & CEO) — $1M. Giraudo Bryan (COO/CFO) — $118,220. Smith Robert Paul JR (Chief Commercial Officer) — $15,050.
The last purchase of 372,000 shares for transaction amount of $250,282 was made by Hasnain Faheem (President & CEO) on 2024‑06‑21.
List of Insider Buy and Sell Transactions, Gossamer Bio, Inc.
| 2024-06-24 | Sale | Chief Medical Officer | 1,908 0.0007% | $0.66 | $1,260 | +9.39% | ||
| 2024-06-21 | President & CEO | 372,000 0.2168% | $0.67 | $250,282 | +38.26% | |||
| 2024-06-18 | COO/CFO | 100,000 0.0512% | $0.59 | $59,110 | +65.19% | |||
| 2024-06-17 | Chief Commercial Officer | 25,000 0.013% | $0.60 | $15,050 | +71.91% | |||
| 2024-03-27 | Sale | EVP, Tech Ops and Admin | 6,430 0.0028% | $1.16 | $7,430 | -26.66% | ||
| 2024-03-27 | Sale | President & CEO | 23,172 0.0101% | $1.16 | $26,773 | -26.66% | ||
| 2024-03-27 | Sale | COO/CFO | 6,430 0.0028% | $1.16 | $7,431 | -26.66% | ||
| 2024-03-18 | Sale | Chief Medical Officer | 4,018 0.0017% | $1.33 | $5,342 | -36.69% | ||
| 2024-03-18 | Sale | EVP, Regulatory Affairs | 4,018 0.0017% | $1.33 | $5,343 | -36.69% | ||
| 2023-11-15 | director | 32,000 0.0139% | $0.79 | $25,213 | +11.11% | |||
| 2023-11-13 | COO/CFO | 200,000 0.0795% | $0.56 | $112,880 | +40.06% | |||
| 2023-06-22 | Sale | Chief Medical Officer | 1,814 0.0018% | $1.29 | $2,340 | -34.29% | ||
| 2023-04-04 | COO/CFO | 55,000 0.0583% | $1.02 | $56,095 | +3.45% | |||
| 2023-03-16 | Sale | Chief Medical Officer | 7,563 0.0083% | $1.10 | $8,304 | 0.00% | ||
| 2023-03-16 | Sale | Chief Scientific Officer | 6,029 0.0066% | $1.10 | $6,620 | 0.00% | ||
| 2023-03-16 | Sale | EVP, Regulatory Affairs | 7,564 0.0083% | $1.10 | $8,305 | 0.00% | ||
| 2022-10-24 | Sale | Chief Medical Officer | 4,757 0.0056% | $12.07 | $57,431 | -88.94% | ||
| 2022-10-24 | Sale | Chief Scientific Officer | 4,876 0.0058% | $12.07 | $58,868 | -88.94% | ||
| 2022-10-24 | Sale | EVP, Regulatory Affairs | 4,757 0.0056% | $12.07 | $57,431 | -88.94% | ||
| 2022-07-15 | President & CEO | 138,696 0.099% | $7.21 | $999,998 | -79.92% |
Insider Historical Profitability
| Hasnain Faheem | President & CEO | 5408073 2.3866% | $0.84 | 4 | 2 | <0.0001% |
| Christian Waage | EVP, Tech Ops and Admin | 585934 0.2586% | $0.84 | 4 | 3 | <0.0001% |
| Giraudo Bryan | COO/CFO | 480010 0.2118% | $0.84 | 9 | 3 | <0.0001% |
| Smith Robert Paul JR | Chief Commercial Officer | 25000 0.011% | $0.84 | 1 | 0 | |
| Gujrathi Sheila | President & CEO | 4048242 1.7865% | $0.84 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Nea Management Company Llc | $18.69M | 7 | 15.84M | 0% | +$0 | 0.09 | |
| Artal Group S A | $15.7M | 5.88 | 13.31M | +10.37% | +$1.47M | 0.07 | |
| The Vanguard Group | $13.88M | 5.2 | 11.76M | +1.1% | +$151,217.00 | <0.0001 | |
| Ecor1 Capital Llc | $10.85M | 4.07 | 9.2M | 0% | +$0 | 0.08 | |
| Octagon Capital Advisors LP | $10.84M | 4.06 | 9.19M | 0% | +$0 | 0.06 |